ATE269701T1 - Gyrase-inhibitoren und ihre verwendung - Google Patents

Gyrase-inhibitoren und ihre verwendung

Info

Publication number
ATE269701T1
ATE269701T1 AT01903077T AT01903077T ATE269701T1 AT E269701 T1 ATE269701 T1 AT E269701T1 AT 01903077 T AT01903077 T AT 01903077T AT 01903077 T AT01903077 T AT 01903077T AT E269701 T1 ATE269701 T1 AT E269701T1
Authority
AT
Austria
Prior art keywords
gyrase inhibitors
gyrase
inhibitors
Prior art date
Application number
AT01903077T
Other languages
English (en)
Inventor
Paul Charifson
Dean Stamos
Michael Badia
Anne-Laure Grillot
Steven Ronkin
Martin Trudeau
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Application granted granted Critical
Publication of ATE269701T1 publication Critical patent/ATE269701T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01903077T 2000-01-18 2001-01-16 Gyrase-inhibitoren und ihre verwendung ATE269701T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17667100P 2000-01-18 2000-01-18
US25433100P 2000-12-08 2000-12-08
PCT/US2001/001374 WO2001052845A1 (en) 2000-01-18 2001-01-16 Gyrase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
ATE269701T1 true ATE269701T1 (de) 2004-07-15

Family

ID=26872470

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01903077T ATE269701T1 (de) 2000-01-18 2001-01-16 Gyrase-inhibitoren und ihre verwendung

Country Status (23)

Country Link
US (2) US6608087B1 (de)
EP (1) EP1251848B1 (de)
JP (1) JP2003520233A (de)
CN (1) CN1230166C (de)
AR (1) AR027518A1 (de)
AT (1) ATE269701T1 (de)
AU (1) AU782883B2 (de)
BR (1) BR0107713A (de)
CA (1) CA2397686A1 (de)
CO (1) CO5261612A1 (de)
DE (1) DE60103974T2 (de)
DK (1) DK1251848T3 (de)
EA (1) EA005680B1 (de)
ES (1) ES2222336T3 (de)
HK (1) HK1053984B (de)
MX (1) MXPA02007134A (de)
MY (1) MY133572A (de)
NZ (1) NZ520628A (de)
PT (1) PT1251848E (de)
SI (1) SI1251848T1 (de)
TR (1) TR200401735T4 (de)
TW (1) TWI287449B (de)
WO (1) WO2001052845A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1389194A2 (de) * 2001-04-27 2004-02-18 Vertex Pharmaceuticals Incorporated Bace-inhibitoren
ATE325608T1 (de) * 2001-08-13 2006-06-15 Janssen Pharmaceutica Nv 2,4,5-trisubstituted thiazolyl derivative und deren antiinflammatorische wirkung
US6984652B2 (en) * 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
FR2865733B1 (fr) * 2004-02-04 2007-10-12 Merck Sante Sas Derives de thiazolylimidazole, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en medecine
EP1819721A1 (de) * 2004-11-19 2007-08-22 Plant Bioscience Limited Microcin-b17-analoga und verfahren zu ihrer herstellung und anwendung
JP4058106B2 (ja) 2005-02-18 2008-03-05 アストラゼネカ アクチボラグ 抗菌性のピペリジン誘導体
US20090264342A1 (en) * 2006-02-13 2009-10-22 Trustees Of Boston University Compositions and methods for antibiotic potentiation and drug discovery
CA2662901A1 (en) 2006-06-21 2007-12-27 Cook Incorporated Fistula grafts and related methods and systems useful for treating gastrointestinal fistulae
US20100234348A1 (en) * 2006-08-04 2010-09-16 Trustees Of Boston University Compositions and methods for potentiating antibiotic activity
TW200906412A (en) * 2007-06-12 2009-02-16 Astrazeneca Ab Piperidine compounds and uses thereof
CN101918389A (zh) * 2007-11-02 2010-12-15 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
WO2009115572A2 (en) * 2008-03-21 2009-09-24 Novartis Ag Novel heterocyclic compounds and uses therof
US8865732B2 (en) * 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
KR20100122513A (ko) * 2008-07-17 2010-11-22 아사히 가세이 파마 가부시키가이샤 질소 함유 복소환 화합물
US8536185B2 (en) * 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
TW201026695A (en) 2008-12-12 2010-07-16 Astrazeneca Ab Piperidine compounds and uses thereof-596
TW201026694A (en) 2008-12-12 2010-07-16 Astrazeneca Ab Compound 468
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2010090716A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US9090601B2 (en) * 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
TW201102065A (en) 2009-05-29 2011-01-16 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
TW201111380A (en) 2009-08-26 2011-04-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
CA2784647A1 (en) * 2009-12-17 2011-07-14 Merck Patent Gmbh Inhibitors of sphingosine kinase
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
TW201217365A (en) 2010-08-11 2012-05-01 Millennium Pharm Inc Heteroaryls and uses thereof
TW201307309A (zh) 2010-10-13 2013-02-16 Millennium Pharm Inc 雜芳基化合物及其用途
CN102911173A (zh) * 2012-11-08 2013-02-06 苏州施亚生物科技有限公司 5,6,7,8-四氢-2H-吡啶并[4,3-c]哒嗪-3-酮的合成方法
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US20170007615A1 (en) 2014-02-03 2017-01-12 Biota Europe Ltd Antibacterial Compounds
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
CA3057431A1 (en) 2017-03-24 2018-09-27 Taisho Pharmaceutical Co., Ltd. 2(1h)-quinolinone derivative
CA3057969A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
WO2018213185A1 (en) 2017-05-17 2018-11-22 Drexel University Rela inhibitors for biofilm disruption
EP3847172A1 (de) 2018-09-03 2021-07-14 Univerza v Ljubljani Neue klasse von dna-gyrase- und/oder topoisomerase-iv-inhibitoren mit aktivität gegen grampositive und gramnegative bakterien
EP3969449B1 (de) 2019-05-13 2025-02-12 Novartis AG Neue kristalline formen von n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluormethyl)isonicotinamid als raf-inhibitoren zur behandlung von krebs
WO2022129327A1 (en) 2020-12-17 2022-06-23 Univerza V Ljubljani New n-phenylpyrrolamide inhibitors of dna gyrase and topoisomerase iv with antibacterial activity
NL2033609B1 (en) * 2022-11-24 2024-05-30 Innes John Centre DNA Gyrase Inhibitors
CN120418231A (zh) * 2022-12-30 2025-08-01 阿勒泰治疗公司 2-取代噻唑和苯并噻唑组合物和作为dux4抑制剂的方法
EP4663242A1 (de) * 2024-06-11 2025-12-17 Helmholtz-Zentrum für Infektionsforschung GmbH Targeting des energiekopplungsfaktor (ecf)-transporters als neues antimikrobielles target

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925659A (en) * 1996-05-07 1999-07-20 Merck & Co., Inc. Antibacterial agents
RU2173147C2 (ru) * 1996-05-09 2001-09-10 Санкио Компани Лимитед Применение производных 1-метилкарбопенема, антибактериальная в отношении helicobacter pylori композиция, содержащая в качестве активного ингредиента 1-метилкарбопенемовые производные и способ профилактики или лечения инфекционных заболеваний

Also Published As

Publication number Publication date
SI1251848T1 (en) 2004-12-31
DK1251848T3 (da) 2004-10-18
DE60103974D1 (de) 2004-07-29
CN1230166C (zh) 2005-12-07
EA005680B1 (ru) 2005-04-28
MY133572A (en) 2007-11-30
AU782883B2 (en) 2005-09-08
NZ520628A (en) 2004-05-28
MXPA02007134A (es) 2003-03-27
CN1400898A (zh) 2003-03-05
JP2003520233A (ja) 2003-07-02
ES2222336T3 (es) 2005-02-01
HK1053984B (zh) 2006-07-28
EP1251848B1 (de) 2004-06-23
TWI287449B (en) 2007-10-01
DE60103974T2 (de) 2005-06-30
US6608087B1 (en) 2003-08-19
BR0107713A (pt) 2002-11-19
HK1053984A1 (en) 2003-11-14
EP1251848A1 (de) 2002-10-30
TR200401735T4 (tr) 2004-08-23
PT1251848E (pt) 2004-10-29
CO5261612A1 (es) 2003-03-31
AR027518A1 (es) 2003-04-02
CA2397686A1 (en) 2001-07-26
US6930116B2 (en) 2005-08-16
AU3094001A (en) 2001-07-31
US20040024030A1 (en) 2004-02-05
WO2001052845A1 (en) 2001-07-26
EA200200769A1 (ru) 2002-12-26

Similar Documents

Publication Publication Date Title
ATE269701T1 (de) Gyrase-inhibitoren und ihre verwendung
NO20032668D0 (no) Gyraseinhibitorer og anvendelser derav
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
IS6656A (is) Útskiptar kínasólínafleiður og notkun þeirra sem hemla
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DE60106423D1 (de) Entzündungshemmende verbindungen und ihre verwendung
NO20042147L (no) Heterocykliske forbindelser og fremgangsmater for anvendelse derav
NO20022656L (no) Caspaseinhibitorer og anvendelse derav
NO20040469L (no) Heterocykliske forbindelser samt fremstilling og anvendelse derav
DK1122244T3 (da) Uracilforbindelser og anvendelse deraf
NO20020343D0 (no) Kaspase-inhibitorer og anvendelse derav
EP1412378A4 (de) Aptamere und antiaptamere
EE200200550A (et) Karbamaatsed kaspaasi inhibiitorid ja nende kasutamine
DE60209486D1 (de) Pyranoindazole und ihre verwendung in der glaukombehandlung
ATE329906T1 (de) Substituierte 2-anilino-benzimidazole und ihre verwendung als nhe-inhibitoren
DE60235252D1 (de) Aromatische methyltransferasen und ihre verwendung
DE60112635D1 (de) Ölzusammensetzung und ihre Verwendung
DE50313157D1 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
DE50206094D1 (de) Substituierte isoindole und ihre verwendung
ATE382040T1 (de) Acylaminothiazolderivate und ihre vewrendung als beta-amyloid inhibitoren
DE50106596D1 (de) Haftklebemasse und ihre verwendung
EE200300491A (et) 6-asendis asendatud indolinoonid ja nende kasutamine kinaas-inhibiitoritena
DE50008549D1 (de) Triazolotriazinone und ihre verwendung
DE60141871D1 (de) Oligonukleotidmarkierungsstoffe und ihre Verwendung
DE50202730D1 (de) Substituierte isoindole und ihre verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1251848

Country of ref document: EP

REN Ceased due to non-payment of the annual fee